⌘K
t
| Date | 23 Feb 2022 |
| Time | 17:00:07 |
| Category | Director/PDMR dealings |
| ID | 6136C |
23 February 2022
genedrive plc
("genedrive" or the "Company")
Director/PDMR Notification
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, makes the following announcement regarding a transaction in the Company's ordinary shares by Matthew Fowler, outgoing Chief Financial Officer.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a. |
Name |
Matthew Fowler
|
||||
|
2. |
Reason for the notification |
|||||
|
a. |
Position/status |
Chief Financial Officer |
||||
|
b. |
Initial notification /Amendment |
Initial |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a. |
Name |
genedrive plc |
||||
|
b. |
LEI |
213800ZYODIRZ87Y4K14 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a. |
Description of the Financial instrument, type of instrument Identification code |
Ordinary Shares of 1.5p each
GB00B1VKB244 |
||||
|
b. |
Nature of the transaction |
Disposal of ordinary shares
|
||||
|
c. |
Price(s) and volume(s) |
|
||||
|
d. |
Aggregated information · Aggregated volume · Price
|
86,957 Ordinary Shares
17.5p per Ordinary Share |
||||
|
e. |
Date of the transaction |
23 February 2022 |
||||
|
f. |
Place of the transaction |
London Stock Exchange, AIM Market (XLON)
|
||||
For further details please contact:
|
genedrive plc |
+44 (0)161 989 0245 |
|
David Budd: CEO / Matthew Fowler: CFO |
|
|
|
|
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+44 (0)20 7418 8900 |
|
James Steel |
|
|
|
|
|
finnCap (Joint Broker) |
+44 (0)20 7220 0500 |
|
Geoff Nash / Kate Bannatyne / Alice Lane |
|
|
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
+44 (0)20 7933 8780 or genedrive@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
+44 (0)7980 541 893 / +44 (0)7876 741 001 |
About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets and a high throughput SARS-CoV-2 assay. The Company has also recently launched a test to help in the prevention of hearing loss caused by certain antibiotics in neonates.